Switching from Wegovy to Zepbound

Overview

Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are both FDA-approved for chronic weight management in adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one weight-related condition. Although both are weekly injections used for the same indication, they contain different active ingredients with different mechanisms of action.

Wegovy is a GLP-1 receptor agonist. Zepbound is a dual GIP and GLP-1 receptor agonist that acts on two incretin hormone pathways. Because these are different medications, switching between them requires restarting the titration process from the beginning.

Always switch medications under the guidance of your healthcare provider. Do not adjust doses without consulting your prescriber.

Why Patients Consider Switching

Patients and their healthcare providers may discuss switching from Wegovy to Zepbound for several reasons:

• Weight-loss plateau: Some patients plateau after an extended period on Wegovy and may wish to explore whether a different mechanism produces further benefit.
• Side effect profile: Individual tolerability can differ between the two. A patient who experiences persistent side effects on one medication may tolerate the other better, though this is not guaranteed.
• Dual mechanism interest: The SURMOUNT-1 trial demonstrated mean weight reductions of approximately 15% to 20.9% with tirzepatide (depending on dose), while the STEP 1 trial showed approximately 14.9% with semaglutide 2.4 mg. Cross-trial comparisons have significant limitations and individual results vary.
• Supply or access issues: Medication availability may influence treatment decisions.

Dose Equivalence: There Is None

There is no direct dose equivalence between semaglutide and tirzepatide. Even if a patient has been on the maximum maintenance dose of Wegovy (2.4 mg weekly), switching to Zepbound requires starting at the beginning of the Zepbound titration schedule:

• Zepbound starting dose: 2.5 mg once weekly for 4 weeks
• Titration steps: 5 mg, then 7.5 mg, then 10 mg, then 12.5 mg, then 15 mg
• Minimum 4 weeks at each dose before increasing
• Maintenance dose range: 5 mg to 15 mg, determined by your provider based on response and tolerability

Skipping the titration or starting at a higher dose increases the risk of significant gastrointestinal side effects and is not recommended.

What to Expect

During early titration: Restarting at a low dose after a maintenance dose of Wegovy may result in reduced appetite suppression or a temporary change in weight trajectory. This is expected and does not indicate the medication is ineffective.

Gastrointestinal effects: Nausea, diarrhea, vomiting, constipation, and stomach pain are common with both medications. Even patients who had adjusted to these effects on Wegovy may experience them again when starting Zepbound. Symptoms typically improve as the body adjusts to each new dose level.

Overlap period: Your healthcare provider will advise on timing. Typically, the first Zepbound injection replaces the next scheduled Wegovy injection. There is no need for a washout period between the two medications, but the specific timing should be determined by your provider.

Reaching full effect: It may take 4 to 6 months to reach the target maintenance dose of Zepbound. Patience during this period is important, and regular follow-up with your healthcare provider helps ensure the transition is proceeding appropriately.

Insurance and Prior Authorization

Switching between weight-management medications can involve additional administrative steps:

• New prior authorization: Most plans require separate prior authorization for Zepbound, even if Wegovy was previously approved.
• Coverage differences: Some plans may cover one medication but not the other. Verify coverage before initiating the switch.
• Documentation requirements: Plans may require documentation of the clinical rationale for switching, such as insufficient response or intolerance.
• Cost differences: Copay amounts and formulary tier placement may differ. Manufacturer savings programs have different eligibility criteria.

Contact your insurance plan and pharmacy early to avoid treatment gaps during the prior authorization process.

Important Reminders

• Do not switch medications or adjust doses without consulting your healthcare provider
• Restarting titration from the lowest dose is a safety requirement, not a setback
• Report persistent or severe side effects to your healthcare provider
• Continue attending follow-up appointments during and after the transition
• Maintain dietary and physical activity recommendations throughout the switch